26197 Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil
2021 ◽
Vol 85
(3)
◽
pp. AB88
Keyword(s):
Phase 3
◽